FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jean-Louis Excler

Research Profile

Chemicals & Drugs

Living Beings

Disorders

Concepts & Ideas

Immunization Schedule

Procedures

Anatomy

Phenomena

HIV Seronegativity

Co-author Network

Publications

TOP 3
Sanjay Mehendale; Ramesh Paranjape; James Ackland; Josephine H Cox; Len Dally; Jean-Louis Excler; Jill Gilmour; Rajat Goyal; Sonali Kochhar; Makesh Kumar; Vasanthapuram Kumaraswami; Swarali Kurle; Seema Sahay; Pattabiraman Sathyamurthi; Eddy Sayeed; Ashwini Shete; Aparna Shrotri; Madhuri Thakar; Amita Verma; Devika Zachariah; Vadakkuppatu Devasenapathi Ramanathan
Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers.
Sorachai Nitayaphan; Robert O'Connell; Viseth Ngauy; Jean-Louis Excler
HIV epidemic in Asia: optimizing and expanding vaccine development.
Silvia Ratto-Kim; Merlin L Robb; Eddy Sayeed; Doris Thelian; Anais Valencia-Micolta; Josephine H Cox; Jeffrey R Currier; Patricia L Earl; Jean-Louis Excler; Jerome H Kim; Vicky Lo; Nelson L Michael; Bernard Moss; Victoria R Polonis; Mary A Marovich
Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jean-Louis Excler (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sanjay Mehendale; Ramesh Paranjape; James Ackland; Josephine H Cox; Len Dally; Jean-Louis Excler; Jill Gilmour; Rajat Goyal; Sonali Kochhar; Makesh Kumar; Vasanthapuram Kumaraswami; Swarali Kurle; Seema Sahay; Pattabiraman Sathyamurthi; Eddy Sayeed; Ashwini Shete; Aparna Shrotri; Madhuri Thakar; Amita Verma; Devika Zachariah; Vadakkuppatu Devasenapathi Ramanathan
Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers.
PloS one 2013;8(2):e55831.
2012: Sorachai Nitayaphan; Robert O'Connell; Viseth Ngauy; Jean-Louis Excler
HIV epidemic in Asia: optimizing and expanding vaccine development.
Expert review of vaccines 2012;11(7):805-19.
2012: Silvia Ratto-Kim; Merlin L Robb; Eddy Sayeed; Doris Thelian; Anais Valencia-Micolta; Josephine H Cox; Jeffrey R Currier; Patricia L Earl; Jean-Louis Excler; Jerome H Kim; Vicky Lo; Nelson L Michael; Bernard Moss; Victoria R Polonis; Mary A Marovich
Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.
PloS one 2012;7(9):e45840.
2012: Michael C Keefer; Wendy Komaroff; Jakub Kopycinski; Kelley Loughran; Marloes Naarding; Eddy Sayeed; Tony Tarragona-Fiol; Sabrina Welsh; Devika Zachariah; James Ackland; Burc Barin; Catherine A Bunce; Michelle Cashin-Cox; Hannah Cheeseman; Lorna Clark; Emmanuel Cormier; Josephine H Cox; Patricia Fast; Natalia Fernandez; Dilbinder Gill; Jill Gilmour; Lottie Hachaambwa; Christine M Hay; Peter Hayes; Jean-Louis Excler
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
PloS one 2012;7(8):e41936.
2011: Hiroto Hara; Hiroto Hara; Mamoru Hasegawa; Takashi Hironaka; Akihiro Iida; Makoto Inoue; Anatoli Kamali; Etienne Karita; Marietta Krebs; Angela Lombardo; Lawrence Mwananyanda; Yoshiyuki Nagai; Christopher L Parks; Matthew A Price; Eduard J Sanders; Eddy Sayeed; Tsugumine Shu; Sandhya Vasan; James Ackland; Omu Anzala; Emmanuel Cormier; Ann R Falsey; Jean-Louis Excler
Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors.
Human vaccines 2011;7(6):639-45.
2011: Jean-Louis Excler; Wasima Rida; Frances Priddy; Jill Gilmour; Adrian B McDermott; Anatoli Kamali; Omu Anzala; Gaudensia Mutua; Eduard J Sanders; Wayne Koff; Seth Berkley; Patricia Fast
AIDS vaccines and preexposure prophylaxis: is synergy possible?
AIDS research and human retroviruses 2011;27(6):669-80.
2010: Jerome H Kim; Supachai Rerks-Ngarm; Jean-Louis Excler; Nelson L Michael
HIV vaccines: lessons learned and the way forward.
Current opinion in HIV and AIDS 2010;5(5):428-34.
2009: Vadakkuppatu Devasenapathi Ramanathan; Makesh Kumar; Jayashri Mahalingam; Pattabiraman Sathyamoorthy; Paranji Ramaiyengar Narayanan; Suniti Solomon; Dennis Panicali; Sekhar Chakrabarty; Josephine Cox; Eddy Sayeed; James Ackland; Carl Verlinde; Dani Vooijs; Kelley Loughran; Burc Barin; Angela Lombardo; Jill Gilmour; Gwynneth Stevens; Michelle Seth Smith; Tony Tarragona-Fiol; Peter Hayes; Sonali Kochhar; Jean-Louis Excler; Patricia Fast
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
AIDS research and human retroviruses 2009;25(11):1107-16.
2008: Jean-Louis Excler; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Yiming Shao; Linqi Zhang; Hiko Tamashiro; Saladin Osmanov
Expanding research capacity and accelerating AIDS vaccine development in Asia.
The Southeast Asian journal of tropical medicine and public health 2008;39(4):766-84.
2008: Jean-Louis Excler; Sonali Kochhar; Sushma Kapoor; Sweta Das; Jyoti Bahri; Meenakshi Datta Ghosh; N K Ganguly; Anjali Nayyar; Mark Chataway
Preparedness for AIDS vaccine trials in India.
The Indian journal of medical research 2008;127(6):531-8.
2008: Sanjay Mehendale; Jan van Lunzen; Nathan Clumeck; Jurgen Rockstroh; Eva Vets; Philip R Johnson; Pervin Anklesaria; Burc Barin; Mark Boaz; Sonali Kochhar; Jennifer Lehrman; Claudia Schmidt; Mathieu Peeters; Carolynne Schwarze-Zander; Kabeya Kabamba; Tobias Glaunsinger; Seema Sahay; Madhuri R Thakar; Ramesh S Paranjape; Jill Gilmour; Jean-Louis Excler; Patricia Fast; Alison E Heald
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.
AIDS research and human retroviruses 2008;24(6):873-80.
2007: Jean-Louis Excler; Wasima Rida; Frances Priddy; Patricia Fast; Wayne Koff
A strategy for accelerating the development of preventive AIDS vaccines.
AIDS (London, England) 2007;21(17):2259-63.
2006: Katherine Luzuriaga; Marie-Louise Newell; François Dabis; Jean-Louis Excler; John L Sullivan
Vaccines to prevent transmission of HIV-1 via breastmilk: scientific and logistical priorities.
Lancet 2006;368(9534):511-21.
2006: Jean-Louis Excler
AIDS vaccine efficacy trials: expand capacity and prioritize. 'Throughout Africa, Asia and Latin America state-of-the-art clinics and laboratories...exist where, 4 years ago, there were none'.
Expert review of vaccines 2006;5(2):167-70.
2005: Jean-Louis Excler
AIDS vaccine development: perspectives, challenges & hopes.
The Indian journal of medical research 2005;121(4):568-81.
2004: Marie Paule Kieny; Jean-Louis Excler; Marc Girard
Research and development of new vaccines against infectious diseases.
American journal of public health 2004;94(11):1931-5.
2003: Patricia A Morgan; Suchada Chinaworapong; Jean-Louis Excler; Siriluck Wongkamheng; Attapon Triampon; Puangmalee Buapunth; Sorachai Nitayaphan; Rodney A Michael; Pricha Singharaj; Arthur E Brown
A joint clinical research center in Thailand: role in HIV vaccine development.
The Southeast Asian journal of tropical medicine and public health 2003;34(1):126-35.
2001: Robert B Belshe; C Stevens; Geoffrey J Gorse; Susan Buchbinder; Kent J Weinhold; Haynes W Sheppard; Donald Stablein; S Self; James McNamara; Sharon Frey; J Flores; Jean-Louis Excler; M Klein; R E Habib; AM Duliege; Clayton D Harro; Lawrence Corey; Michael C Keefer; Mark MULLIGAN; P Wright; Connie Celum; Franklyn N Judson; K Mayer; David J McKirnan; Michael Marmor; George E Woody
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
The Journal of infectious diseases 2001;183(9):1343-52.
2000: F Verrier; Sherri Burda; Robert B Belshe; AM Duliege; Jean-Louis Excler; M Klein; Susan Zolla-Pazner
A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
Journal of virology 2000;74(21):10025-33.
2000: M Raux; Laurent Finkielsztejn; Dominique Salmon-Céron; H Bouchez; Jean-Louis Excler; Emmanuel Dulioust; JM Grouin; Didier Sicard; C Blondeau
IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects.
AIDS research and human retroviruses 2000;16(6):583-94.
1999: M Raux; Laurent Finkielsztejn; Dominique Salmon-Céron; H Bouchez; Jean-Louis Excler; Emmanuel Dulioust; JM Grouin; Didier Sicard; C Blondeau
Comparison of the distribution of IgG and IgA antibodies in serum and various mucosal fluids of HIV type 1-infected subjects.
AIDS research and human retroviruses 1999;15(15):1365-76.
1999: Thomas G Evans; Michael C Keefer; Kent J Weinhold; Mark Wolff; David Montefiori; Geoffrey J Gorse; Barney S Graham; M Juliana McElrath; Mary Lou Clements-Mann; Mark MULLIGAN; Patricia Fast; MC Walker; Jean-Louis Excler; AM Duliege; Jim Tartaglia
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
The Journal of infectious diseases 1999;180(2):290-8.
1999: Dominique Salmon-Céron; Jean-Louis Excler; Laurent Finkielsztejn; Brigitte Autran; J C Gluckman; Didier Sicard; TJ Matthews; B Meignier; C Valentin; Raphaelle El Habib; C Blondeau; M Raux; Christiane Moog; Jim Tartaglia; P Chong; M Klein; B Milcamps; F Heshmati; Stanley Plotkin
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
AIDS research and human retroviruses 1999;15(7):633-45.
1999: M Raux; Laurent Finkielsztejn; Dominique Salmon-Céron; H Bouchez; Jean-Louis Excler; Emmanuel Dulioust; JM Grouin; Didier Sicard; C Blondeau
Development and standardization of methods to evaluate the antibody response to an HIV-1 candidate vaccine in secretions and sera of seronegative vaccine recipients.
Journal of immunological methods 1999;222(1-2):111-24.
1998: Robert B Belshe; Geoffrey J Gorse; Mark MULLIGAN; Thomas G Evans; Michael C Keefer; Jean-Louis Excler; AM Duliege; Jim Tartaglia; W I Cox; James McNamara; K L Hwang; A Bradney; David Montefiori; Kent J Weinhold
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
AIDS (London, England) 1998;12(18):2407-15.
1998: Susan Zolla-Pazner; S Xu; Sherri Burda; AM Duliege; Jean-Louis Excler; Mary Lou Clements-Mann
Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines.
The Journal of infectious diseases 1998;178(5):1502-6.
1998: Jim Tartaglia; Jean-Louis Excler; Raphaelle El Habib; K Limbach; B Meignier; Stanley Plotkin; M Klein
Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV.
AIDS research and human retroviruses 1998;14 Suppl 3():S291-8.
1998: Mary Lou Clements-Mann; Kent J Weinhold; TJ Matthews; Barney S Graham; Geoffrey J Gorse; Michael C Keefer; M Juliana McElrath; RH Hsieh; Jiri Mestecky; Susan Zolla-Pazner; J Mascola; David H Schwartz; Robert Siliciano; Lawrence Corey; Peter F Wright; Robert B Belshe; Raphael Dolin; S Jackson; S Xu; Patricia Fast; MC Walker; Donald Stablein; Jean-Louis Excler; Jim Tartaglia; E Paoletti
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1998;177(5):1230-46.
1997: E Coëffier; Jean-Louis Excler; Marie Paule Kieny; B Meignier; C Moste; Jim Tartaglia; Gilles Pialoux; Dominique Salmon-Céron; CLAUDE LECLERC
Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines.
AIDS research and human retroviruses 1997;13(17):1471-85.
1997: Susan Zolla-Pazner; C Alving; Robert B Belshe; Phillip W. Berman; Sherri Burda; P Chigurupati; M L Clements; AM Duliege; Jean-Louis Excler; Catarina E Hioe; J Kahn; M Juliana McElrath; S Sharpe; F Sinangil; K Steimer; MC Walker; N Wassef; S Xu
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines.
The Journal of infectious diseases 1997;175(4):764-74.
1997: Guido Ferrari; W Humphrey; M Juliana McElrath; Jean-Louis Excler; AM Duliege; M L Clements; Lawrence Corey; Dani P Bolognesi; Kent J Weinhold
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(4):1396-401.
1997: Jean-Louis Excler; Stanley Plotkin
The prime-boost concept applied to HIV preventive vaccines.
AIDS (London, England) 1997;11 Suppl A():S127-37.
1996: B Fleury; G Janvier; G Pialoux; Florence Buseyne; M N Robertson; Jim Tartaglia; E Paoletti; Marie Paule Kieny; Jean-Louis Excler; Yves Rivière
Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160.
The Journal of infectious diseases 1996;174(4):734-8.
1996: Cécile Kaplan; M C Morel-Kopp; Marie Paule Kieny; H Kolbe; P Salmon; Didier Sicard; G Pialoux; B Meignier; Jean-Louis Excler; Stanley Plotkin
Antiplatelet antibodies during the course of HIV-preventive vaccine trial.
AIDS (London, England) 1996;10(4):447-9.
1996: J P Moulia-Pelat; André Spiegel; Jean-Louis Excler; Paul Martin; J F Roux; Jean-Paul Boutin; C Blondeau; P Saliou
[Control of hepatitis B in French Polynesia with a program of systematic vaccination of newborns with the Genhevac B vaccine].
Santé (Montrouge, France) 1996;6(1):11-5.
1995: Dominique Salmon-Céron; Jean-Louis Excler; Didier Sicard; P Blanche; L Finkielstzjen; Jean Claude Gluckman; B Autran; TJ Matthews; B Meignier; Marie Paule Kieny
Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
AIDS research and human retroviruses 1995;11(12):1479-86.
1995: Bruno Marchou; Jean-Louis Excler; C Bourderioux; J Salaun; N Picot; B Yvonnet; J E Cerisier; H Salomon; J C Auvergnat
A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedules.
The Journal of infectious diseases 1995;172(1):258-60.
1995: G Pialoux; Jean-Louis Excler; Yves Rivière; G Gonzalez-Canali; V Feuillie; P Coulaud; Jean Claude Gluckman; TJ Matthews; B Meignier; Marie Paule Kieny
A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.
AIDS research and human retroviruses 1995;11(3):373-81.
1995: Jean-Louis Excler; B Yvonnet; Y Gaye; A Monnereau; J L Mangin; M Schlumberger; F Mireux; A B Gaye; L C Sarr
[Inclusion of hepatitis B vaccination in the Expanded Program of Immunization: feasibility study in the medical region of Kolda (Senegal)].
Santé (Montrouge, France) 1995;5(1):37-42.
1995: SA Plotkin; M Cadoz; B Meignier; C Méric; Odile Leroy; Jean-Louis Excler; Jim Tartaglia; E Paoletti; E Gonczol; G Chappuis
The safety and use of canarypox vectored vaccines.
Developments in biological standardization 1995;84():165-70.
1994: J P Moulia-Pelat; André Spiegel; P M Martin; R Cardines; Jean-Paul Boutin; J F Roux; Jean-Louis Excler; P Saliou
A 5-year immunization field trial against hepatitis B using a Chinese hamster ovary cell recombinant vaccine in French Polynesian newborns: results at 3 years.
Vaccine 1994;12(6):499-502.
1994: Paul Jungers; P Chauveau; A M Couroucé; A Abbassi; P Devillier; F N Marie; F Bailleux; Jean-Louis Excler; J E Cerisier; P Saliou
[Recombinant vaccine and extracting vaccine against hepatitis B in patients with kidney insufficiency: comparative immunogenicity].
Presse médicale (Paris, France : 1983) 1994;23(6):277-80.
1994: Paul Jungers; P Chauveau; A M Couroucé; P Devillier; Jean-Louis Excler; F Bailleux; P Saliou
Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients.
The Journal of infectious diseases 1994;169(2):399-402.
1993: Bruno Marchou; N Picot; P Chavanet; J C Auvergnat; M Armengaud; P Devilliers; J E Cerisier; F N Marié; Jean-Louis Excler
Three-week hepatitis B vaccination provides protective immunity.
Vaccine 1993;11(14):1383-5.